Please login to the form below

Not currently logged in
Email:
Password:

First new COPD inhaler in 8 years launches

Novartis has launched the Onbrez Breezhaler (indacaterol), a once-daily LABA for use in Chronic Obstructive Pulmonary Disease (COPD), in the UK

The Onbrez Breezhaler (indacaterol), a new 24-hour once-a-day drug for use in Chronic Obstructive Pulmonary Disease (COPD), has been launched in the UK by Novartis. The long-acting beta agonist (LABA) is the first new COPD treatment to be introduced to the UK for eight years and is the first 24-hour once-daily COPD treatment to be available.

The European Medicines Agency (EMA) granted indacaterol an EU-wide licence in November 2009, based on the results of clinical trials in over 2,000 patients. These trials showed that indacaterol provided bronchodilation within five minutes and this effect lasted for 24 hours. This resulted in a clinically significant improvement in breathlessness at six months versus placebo.

Dr Steve Holmes, chair of the Primary Care Respiratory Society and a member of the British Thoracic Society Education Committee, commented: "This new treatment is great news as it offers a once daily treatment for people with COPD suffering from breathlessness. The early research shows significant improvements in patients' quality of life."

Indacaterol is a COPD maintenance therapy and is not for use either as a reliever or to treat asthma.

11th August 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics